California’s low cost insulin hits delays despite Newsom’s push

California’s ambitious CalRx program, designed to provide low cost insulin to diabetes patients, has faced significant delays despite Governor Gavin Newsom’s high profile push for affordable healthcare. While the initiative was announced with fanfare, production and distribution challenges have slowed its rollout, leaving many patients still reliant on expensive alternatives. The setbacks raise questions about the feasibility of state led drug pricing reforms.

California’s CalRx insulin, a state backed initiative to produce affordable insulin, has struggled to reach patients since its launch. Governor Gavin Newsom announced the program in 2020 as part of a broader effort to reduce healthcare costs, positioning California as a leader in drug pricing reform. The state partnered with Civica Rx, a nonprofit generic drug manufacturer, to produce and distribute insulin at a fraction of the cost of brand name versions.

Despite these efforts, the rollout has been slower than expected. While Newsom has touted the program’s potential to save patients hundreds of dollars annually, only a limited number of pharmacies currently stock CalRx insulin. Patients and advocates report difficulty accessing the drug, with some still paying high out of pocket costs for alternatives.